Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Retained Earnings (2021 - 2025)

Prime Medicine's Retained Earnings history spans 5 years, with the latest figure at $82000.0 for Q4 2025.

  • For Q4 2025, Retained Earnings rose 8100.0% year-over-year to $82000.0; the TTM value through Dec 2025 reached $82000.0, up 8100.0%, while the annual FY2025 figure was $82000.0, 8100.0% up from the prior year.
  • Retained Earnings reached $82000.0 in Q4 2025 per PRME's latest filing, up from $33000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $82000.0 in Q4 2025 to a low of -$791.7 million in Q2 2025.
  • Average Retained Earnings over 5 years is -$289.2 million, with a median of -$253.9 million recorded in 2022.
  • The largest YoY upside for Retained Earnings was 8100.0% in 2025 against a maximum downside of 1114970.42% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$171.4 million in 2021, then surged by 99.78% to -$384000.0 in 2022, then plummeted by 127850.52% to -$491.3 million in 2023, then surged by 100.0% to $1000.0 in 2024, then soared by 8100.0% to $82000.0 in 2025.
  • Per Business Quant, the three most recent readings for PRME's Retained Earnings are $82000.0 (Q4 2025), $33000.0 (Q3 2025), and -$791.7 million (Q2 2025).